Tested Applications
Positive FC detected in | human peripheral blood leukocytes |
Recommended dilution
Application | Dilution |
---|---|
This reagent has been pre-titrated and tested for flow cytometric analysis. The suggested use of this reagent is 5 ul per 10^6 cells in a 100 µl suspension or 5 ul per 100 µl of whole blood. | |
Sample-dependent, Check data in validation data gallery. |
Product Information
CL647-98177 targets Siglec-8 in FC applications and shows reactivity with human samples.
Tested Reactivity | human |
Host / Isotype | Rabbit / IgG |
Class | Recombinant |
Type | Antibody |
Immunogen | Recombinant Protein Predict reactive species |
Full Name | sialic acid binding Ig-like lectin 8 |
Calculated Molecular Weight | 499 aa, 54 kDa |
GenBank Accession Number | BC053319 |
Gene Symbol | SIGLEC8 |
Gene ID (NCBI) | 27181 |
Conjugate | CoraLite® Plus 647 Fluorescent Dye |
Excitation/Emission Maxima Wavelengths | 654 nm / 674 nm |
Form | Liquid |
Purification Method | Protein A purification |
UNIPROT ID | Q9NYZ4 |
Storage Buffer | PBS with 0.09% sodium azide and 0.5% BSA. |
Storage Conditions | Store at 2-8°C. Avoid exposure to light. Stable for one year after shipment. |
Background Information
Sialic acid-binding Ig-like lectin 8 (Siglec-8), also known as SAF2, is a sialic acid-binding immunoglobulin-like lectin that belongs to the SIGLEC family of the Ig superfamily (PMID: 10856141). Siglec-8 is a single-pass transmembrane protein containing three extracellular immunoglobulin-like domains, a transmembrane region, and a cytoplasmic tail (PMID: 10625619). It is an inhibitory receptor selectively expressed on human mast cells and eosinophils, and at low levels on basophils (PMID: 10856141; 33374255). Engagement of Siglec-8 with antibody results in inhibiting IgE-mediated mast cell responses and reducing allergic inflammation (PMID: 32814824).
Protocols
Product Specific Protocols | |
---|---|
FC protocol for CL Plus 647 Siglec-8 antibody CL647-98177 | Download protocol |
Standard Protocols | |
---|---|
Click here to view our Standard Protocols |